セファロスポリン系薬の世界市場2015-2019...市場調査レポートについてご紹介

【英文タイトル】Global Cephalosporin Drugs Market 2015-2019

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Top vendor offerings

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights

PART 05: Cephalosporin overview
Introduction
Precursors of cephalosporins
Mechanism of action
General principles for use of antibiotics
Clinical uses
Epidemiology

PART 06: Overview on the consumption of antibiotics
Latin America
Europe
APAC

PART 07: Legislation relating to antibiotic use in the US

PART 08: Market landscape
Market overview
Market size and forecast
Five forces analysis

PART 09: Market segmentation by generation of cephalosporin
First-generation cephalosporins
Second-generation cephalosporins
Third-generation cephalosporins
Fourth-generation cephalosporins
Fifth-generation cephalosporins

PART 10: Market segmentation by route of administration
Injection
Oral

PART 11: Geographical segmentation
Segmentation of global cephalosporin drugs market by geography
Cephalosporin drugs market in Americas
Cephalosporin drugs market in EMEA
Cephalosporin drugs market in APAC

PART 12: Market drivers
Special regulatory designation for pipeline molecules
Rise in prevalence of infectious diseases
Increase in awareness

PART 13: Impact of drivers

PART 14: Market challenges
Development of drug resistance
High generic penetration
Weak pipeline

PART 15: Impact of drivers and challenges

PART 16: Market trends
Use of combination therapies
Increase in M&A
Increasing irrational use of cephalosporins

PART 17: Vendor landscape
Competitive scenario
Market share analysis 2014
Other prominent vendors

PART 18: Key vendor analysis
Allergan
Astellas
Bristol-Myers Squibb
GSK
Merck
Pfizer
Sandoz
Teva Pharmaceuticals

PART 19: Appendix
List of abbreviations

PART 20: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Evolution of cephalosporin drugs
Exhibit 03: Overview of the activity of different generations of cephalosporin drugs
Exhibit 04: General principles involved in use of antibiotics
Exhibit 05: Estimated number of cases for nosocomial infections in the US 2011
Exhibit 06: Number of cases of E.coli in the UK 2012-2014
Exhibit 07: Legislation relating to the use of antibiotics in the US
Exhibit 08: Global cephalosporin drugs market 2014-2019 ($ millions)
Exhibit 09: Five forces analysis
Exhibit 10: Global cephalosporin drugs market segment by generation
Exhibit 11: Overview of activity of different generations of cephalosporins
Exhibit 12: Evolution of different generations of cephalosporin drugs
Exhibit 13: Global cephalosporin drugs market segment by route of administration
Exhibit 14: Different generations of cephalosporin drugs by route of administration
Exhibit 15: Global cephalosporin drugs market segment by geography 2014
Exhibit 16: Global cephalosporin drugs market revenue by geography 2014-2019 ($ millions)
Exhibit 17: Cephalosporin drugs market in Americas 2014-2019 ($ millions)
Exhibit 18: Percentage share of cephalosporin market in Americas
Exhibit 19: Percentage share of market by generation of cephalosporin in the US based on revenue 2014
Exhibit 20: Cephalosporin drugs market in EMEA 2014-2019 ($ millions)
Exhibit 21: Percentage share of cephalosporin drugs market in EMEA
Exhibit 22: Percentage share of market by generation of cephalosporin in EU based on revenue 2014
Exhibit 23: Cephalosporin drugs market in APAC 2014-2019 ($ millions)
Exhibit 24: Impact of drivers
Exhibit 25: Cephalosporin resistant strains according to the period of development of resistance
Exhibit 26: Impact of drivers and challenges
Exhibit 27: Allergan: YoY growth and revenue generated from net product sales of anti-infective drugs 2011-2013 ($ millions)
Exhibit 28: Allergan: Key takeaways
Exhibit 29: Astellas: Key takeaways
Exhibit 30: Bristol-Myers Squibb: Key takeaways
Exhibit 31: GSK: Key takeaways
Exhibit 32: Merck: Key takeaways
Exhibit 33: Pfizer: Key takeaways
Exhibit 34: Sandoz: Key takeaways
Exhibit 35: Teva Pharmaceuticals: Key takeaways
Exhibit 36: Allergan: Business segmentation by product revenue 2014
Exhibit 37: Allergan: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 38: Allergan: Geographical segmentation by revenue 2014
Exhibit 39: Astellas: Product segmentation by revenue 2015
Exhibit 40: Astellas: Product segmentation by revenue 2014 and 2015 ($ billions)
Exhibit 41: Astellas: Geographical segmentation by revenue 2015
Exhibit 42: Bristol-Myers Squibb: Segmentation by revenue 2014
Exhibit 43: Bristol-Myers Squibb: Segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 44: Bristol-Myers Squibb: Geographical segmentation by revenue 2014
Exhibit 45: GSK: Business segmentation by revenue 2014
Exhibit 46: GSK: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 47: GSK: Geographical segmentation by revenue 2014
Exhibit 48: Merck: Business segmentation by revenue 2014
Exhibit 49: Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 50: Merck: Geographical segmentation by revenue 2014
Exhibit 51: Pfizer: Business segmentation by revenue 2014
Exhibit 52: Pfizer business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 53: Pfizer: Geographical segmentation by revenue 2014
Exhibit 54: Sandoz: Business segmentation by revenue 2014
Exhibit 55: Teva Pharmaceuticals: Business segmentation by revenue 2014
Exhibit 56: Teva Pharmaceuticals: Business segmentation by revenue 2013 and 2014
Exhibit 57: Teva Pharmaceuticals: Geographical segmentation by revenue 2014


【レポート販売概要】

■ タイトル:セファロスポリン系薬の世界市場2015-2019
■ 英文:Global Cephalosporin Drugs Market 2015-2019
■ 発行日:2015年9月23日
■ 調査会社:Technavio
■ 商品コード:IRTNTR7550
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。